https://investors.bms.com/iframes/press-releases/press-release-details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx Bristol Myers Squibb Announces Updated Action Date by the U.S.
Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase) Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024 Bristol Myers Squibb (NYSE: BMY) toda...
#
BMS
#
옵디보SC
#
알테오젠
#
SC제형
#
pembrolizumabSC
#
nivolumab
#
MSD
#
keytrudaSC
#
Hybrozyme
#
키트루다SC
원문 링크 : 옵디보sc 허가일정 단축! (키트루다sc도 단축 예상!)
